 Actinium Pharmaceuticals Inc NYSE: ATNM highlighted data from its pivotal Phase 3 SIERRA trial evaluating Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia AML aged 55 years and above. Iomab-B radiotherapy is intended to be a targeted conditioning preparing agent to enable a potentially curative bone marrow transplant BMT. 